[184+ Pages Report] According to Facts and Factors, the global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market was measured at around USD 5,150.4 million in 2020, and is forecast to produce sales of around USD 16,487.4 million by the end of 2026, expanding at a CAGR of around 21.4 percent between 2021 and 2026.
B cell maturation antigen is the target antigen for new MM immunotherapy and plays a role in MM pathophysiology. After dealing with B cell maturation antigen antibody-drug conjugates (ADC), bi-specific T cell engagers and chimeric antigen receptor T, complete responses have been reported in heavily pretreated MM patients. These and further new BCMA-targeted therapies are revolutionizing MM care and patient outcomes.
The CAR T-cell method has been active in some leukemias and lymphomas as a plan to manipulate native antibody or T-cell recognition as well as signaling pathways; the institution of specific genes through viral vectors permits tumor cells to be recognized, resulting in intense post-infusion CAR T-cell expansion and real tumor cell killing. Multiple B-Cell Maturation Antigen -directed CAR T-cell studies have now been conducted around the world, mainly in the USA and China, with similar results of major, rapid activity and huge rates of response-related toxicities such as cytokine release syndrome and neurotoxicity. 14 – 17 One study found that tumor cells expressing as few as 222 BCMA molecules per cell were recognized by the CAR T-cell therapy bb2121, indicating that very low-level BCMA expression appears to be sufficient to activate the killing activity.
When exposed to chemicals or radiations, middle-aged men with a history of monoclonal gammopathy are at the greatest risk of developing multiple myeloma. To provide significant restraints on future growth in the BCMA targeted treatment market, it is critical to raise awareness about the successful treatment of cancer and related diseases among the research community. The global increase in the prevalence of multiple myeloma is projected to fuel the demand for BCMA targeted therapies shortly. Multiple myeloma is cancer that can be terminal and can recur, causing other severe complications. The global prevalence of multiple myeloma and other severe fatal diseases necessitates specific diagnosis and treatment. As a result, there is an urgent need for successful therapies and medical services, which is likely to accelerate the BCMA market's growth in the near future.
The global B-Cell Maturation Antigen (BCMA) targeted therapies market is segregated based on product type, indication and end-users, and region
The B-Cell Maturation Antigen (BCMA) targeted therapies market can be divided into three types of products: CAR-T cells, antibody drug conjugates and specific antibodies. These are the numerous types of B-cell maturation antigen products based on the mechanism or function they perform with other proteins or cells in the body, such as , lysis of malignant multiple myeloma, tumor cell identification and destruction, and antibody conjugate formation. Multiple myeloma and acute lymphoblastic leukemia are the indication segment in global B-Cell Maturation Antigen (BCMA) targeted therapies market. Cancer research institutes and hospitals are the end-user segments of the global B-Cell Maturation Antigen (BCMA) targeted therapies market.
North America is the world's largest market for B-Cell Maturation Antigen (BCMA) targeted therapies market owing to the presence of noticeable market participants coupled with ongoing investment in research and development. Asia Pacific is expected to be the fastest-growing regional market for B-Cell Maturation Antigen (BCMA) targeted therapies market. The second-largest market for B-Cell Maturation Antigen (BCMA) targeted therapies in Europe. Demand is expected to be fuelled shortly by developed nations such as Germany, France, and Italy, among others.
Some main participants of the global B-Cell Maturation Antigen (BCMA) targeted therapies market are Sutro Biopharma, Onyx Pharmaceuticals, GlaxoSmithKline plc, Novartis AG, Gilead Sciences. Inc., Amgen Inc., Affimed N.V, Autolus Ltd., Juno Therapeutics, Malin Corporation, Eureka Therapeutics, Transposagen Biopharmaceuticals, Poseida Therapeutics, Inc., firstVentury Equity, Five Prime Therapeutics, Bluebird Bio, Dana-Farber Cancer Institute, Deerfield Partners, and Celgene Corporation others.
Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.
Still haven't found what you're looking for? Speak to our Custom Research TeamLearn More